Literature DB >> 19267361

Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer.

Sokbom Kang1, Sang-Soo Seo, Sang-Yoon Park.   

Abstract

BACKGROUND: The purpose of this study was to determine the independency of a nadir CA-125 level as a prognostic factor in patients with advanced epithelial ovarian cancer (EOC).
METHODS: Among the 153 women with advanced EOC who had surgery in our hospital between January 2001 and June 2007, 121 women underwent retrospective chart review.
RESULTS: Sixty-six patients (57.9%) had nadir CA-125 values < or =10 U/ml. The CA-125 levels at the time of diagnosis was associated with the nadir CA-125 (P = 0.018). The median progression-free survival (PFS) in patients with nadir CA-125 levels < or =10 and 10-35 U/ml was 32.4 and 16.8 months, respectively (P = 0.0001). A multivariate Cox hazard model revealed that the nadir CA-125 value and the residual tumor size > or =0.5 cm were independently associated with the PFS (P = 0.001 and 0.014). Within the subgroup who underwent primary debulking surgery, the significant association between the PFS and the nadir CA-125 value was preserved (P = 0.001).
CONCLUSIONS: The prognostic role of the nadir CA-125 is independent of residual tumor size in the patients with advanced EOC. However, it is still unclear whether maximal surgical effort can affect the nadir CA-125 levels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19267361     DOI: 10.1002/jso.21258

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  10 in total

Review 1.  Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls.

Authors:  Iván Díaz-Padilla; Albiruni Ryan Abdul Razak; Lucas Minig; Marcus Q Bernardini; Josep María Del Campo
Journal:  Clin Transl Oncol       Date:  2012-01       Impact factor: 3.405

2.  Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial.

Authors:  Leslie M Randall; Michael W Sill; Robert A Burger; Bradley J Monk; Barbara Buening; Joel I Sorosky
Journal:  Gynecol Oncol       Date:  2011-12-01       Impact factor: 5.482

3.  CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.

Authors:  Xiaoxiang Chen; Jing Zhang; Wenjun Cheng; Doo Young Chang; Jianfei Huang; Xuan Wang; Lizhou Jia; Daniel G Rosen; Wei Zhang; Da Yang; David M Gershenson; Anil K Sood; Robert C Bast; Jinsong Liu
Journal:  Int J Gynecol Cancer       Date:  2013-06       Impact factor: 3.437

Review 4.  CA125-related tumor cell kinetics variables after chemotherapy in advanced ovarian cancer: a systematic review.

Authors:  G Colloca; A Venturino; I Governato
Journal:  Clin Transl Oncol       Date:  2015-11-06       Impact factor: 3.405

5.  Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer.

Authors:  Sokbom Kang; Tae-Joong Kim; Sang-Soo Seo; Byoung-Gie Kim; Duk-Soo Bae; Sang-Yoon Park
Journal:  J Gynecol Oncol       Date:  2011-12-05       Impact factor: 4.401

6.  Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer.

Authors:  Xia Xu; Yan Wang; Fang Wang; Lizhou Jia; Yiqin Zhou; Fei Deng; Junwei Qu; Bifang Zhou; Aifeng Meng; Bole Fu; Xiaoxiang Chen; Zhiying Qian; Jinhua Wang
Journal:  J Ovarian Res       Date:  2013-04-25       Impact factor: 4.234

7.  Prognostic value of serum CA-125 in patients with advanced epithelial ovarian cancer followed by complete remission after adjuvant chemotherapy.

Authors:  Jong Ho Moon; Hyo Jin Lee; Woo Dae Kang; Chul Hong Kim; Ho Sun Choi; Seok Mo Kim
Journal:  Obstet Gynecol Sci       Date:  2013-01-09

8.  Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer.

Authors:  Maria Lee; Min Young Chang; Hanna Yoo; Kyung Eun Lee; Doo Byung Chay; Hanbyoul Cho; Sunghoon Kim; Young Tae Kim; Jae-Hoon Kim
Journal:  Yonsei Med J       Date:  2016-05       Impact factor: 2.759

9.  Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer.

Authors:  Szymon Piatek; Grzegorz Panek; Zbigniew Lewandowski; Dominika Piatek; Przemyslaw Kosinski; Mariusz Bidzinski
Journal:  Sci Rep       Date:  2021-09-14       Impact factor: 4.379

10.  Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer.

Authors:  Jorge A Alegría-Baños; José C Jiménez-López; Arely Vergara-Castañeda; David F Cantú de León; Alejandro Mohar-Betancourt; Delia Pérez-Montiel; Gisela Sánchez-Domínguez; Mariana García-Villarejo; César Olivares-Pérez; Ángel Hernández-Constantino; Acitlalin González-Santiago; Miguel Clara-Altamirano; Liz Arela-Quispe; Diddier Prada-Ortega
Journal:  J Ovarian Res       Date:  2021-07-19       Impact factor: 4.234

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.